chloroquine and derivatives - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.10 [0.99, 1.22]< 10%11 studies (11/-)3.8 %some concernlow moderatecrucial-
deaths (time to event analysis only) 1.10 [0.99, 1.23]< 10%2 studies (2/-)3.9 %some concernnot evaluable moderatecrucial-
clinical improvement 1.09 [0.81, 1.46]> 10%2 studies (2/-)71.4 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.14 [0.56, 2.31]> 115%2 studies (2/-)64.3 %some concernnot evaluable moderateimportant-
clinical worsening 1.20 [0.83, 1.72]< 10%3 studies (3/-)16.5 %some concernnot evaluable moderateimportant-
death or ventilation 1.14 [1.03, 1.25]< 10%3 studies (3/-)0.5 %some concernnot evaluable moderateimportant-
PCR-negative conversion 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-
PCR-negative conversion (14-day) 1.09 [0.95, 1.26]> 10%2 studies (2/-)88.8 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.20 [0.60, 2.40]> 10%1 study (1/-)69.7 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1/-)94.7 %some concernnot evaluable moderateimportant-
ICU admission 0.83 [0.35, 1.95]< 10%1 study (1/-)66.8 %some concernnot evaluable moderatenon important-

-- safety endpoints 00

adverse events 1.43 [1.12, 1.81]< 10%6 studies (6/-)0.2 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 95,94,90,91 95, 90